Cynata Therapeutics Limited (FRA:51S)

Market Cap	52.99M +116.4%
Revenue (ttm)	958.55K -3.0%
Net Income	-4.77M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1840
Previous Close	0.1960
Day's Range	0.1840 - 0.1840
52-Week Range	0.0620 - 0.2400
Beta	n/a
RSI	63.18
Earnings Date	May 27, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51S

Financial Performance

In fiscal year 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.

Financial numbers in AUD